DiaMedica reports positive Phase 2 preeclampsia data: BP reductions, no placental transfer

DiaMedica Therapeutics Inc.

DM199 highest dose (Cohort 9, n=3): SBP -35 mmHg (p<0.05), DBP -15 mmHg (p<0.05) at 5 min post-infusion.
Pooled cohorts 6-9 (n=12) showed sustained BP reductions at 5 min, 30 min, and 24 hours (p≤0.0031).
No placental transfer; no serious TEAEs; mild nausea (14%), headache (11%), flushing (4%); no discontinuations.
Uterine artery pulsatility index reduced 13.2% (p=0.0003), indicating improved placental perfusion.
Study to proceed with dose expansion (Part 1b) and initiate fetal growth restriction cohort (Part 3).

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.